According to a new report published by Allied Market Research, titled, “Preimplantation Genetics Diagnosis (PGD) Market,” The preimplantation genetics diagnosis (pgd) market was valued at $81,520.20 thousand in 2020, and is estimated to reach $217,190.00 thousand by 2030, growing at a CAGR of 10.4% from 2021 to 2030.
Rise in health problems associated with hormones have boosted the growth of the global preimplantation genetics diagnosis (PGD) market. However, high costs involved for various diagnosis hamper the market growth. On the contrary, increase in number of patients suffering from genetic disorders and surge in hereditary diseases are expected to open new opportunities in the future.
Download Sample PDF at: (Flash Sale Tell 20th August 2022): https://www.alliedmarketresearch.com/request-sample/1470
Around 30 to 60% of the human embryos have chromosomal abnormalities. They usually occur in women aged 40 and above. Moreover, chromosomal abnormalities are also seen in working women due to the hectic lifestyle patterns which increase the demand of various diagnostic procedures including PGD.
PGD is extensively used in ivf genetic testing for identification of genetic defects in embryos. PGD is effective in reducing chances of conceiving unhealthy embryos. In addition, it significantly increases the chances of successful healthy pregnancy. These factors drive the growth of the market . Furthermore, rise in infertility rate as well as genetic, hereditary, and chromosomal diseases positively influenced the growth of the market. In addition, technological advancements in PGD provide advantages, including ability to prevent disability in offspring and development of unhealthy savior siblings by using PGD with HLA. Furthermore, PGD shown positive response in patients trying to conceive with recurrent IVF failures, low sperm count, and with advance maternal age.
Covid-19 scenario:
The Covid-19 pandemic significantly increased the importance of government healthcare facilities and healthcare expenditure across the globe.
However, as the number of Covid-19 patients have reduced, the companies that offer PGD reopened and established new methods of working post-pandemic.
Specific Requirement on COVID-19? Ask to Our Industry Expert:
https://www.alliedmarketresearch.com/request-for-customization/1470?reqfor=covid
The global preimplantation genetics diagnosis (PGD) market includes an in-depth analysis of the prime market players such as Viatris Inc., Bayer AG, Boehringer Ingelheim GmbH, Endo International plc., GlaxoSmithKline plc., Johnson & Johnson, Novartis AG, Purdue Pharma L.P., Altaris, and Hisamitsu Pharmaceutical Co. Inc.
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.